Dendritic cells and their role in cancer immunotherapy
Автор: Melnikova A.A., Grivtsova L.Yu.
Журнал: Cardiometry @cardiometry
Рубрика: Conference proceedings
Статья в выпуске: 29, 2023 года.
Бесплатный доступ
Cytotoxic CD8+ T lymphocytes (CD8+ CTLs) are key effector cells, which recognize and kill tumor cells, and are therefore preferred targets for improved cancer immunotherapy.
Dendritic cells, cancer immunotherapy, dc vaccines, antitumor t cell response
Короткий адрес: https://sciup.org/148327389
IDR: 148327389 | DOI: 10.18137/cardiometry.2023.29.conf.17
Список литературы Dendritic cells and their role in cancer immunotherapy
- Sahin U, Derhovanessian E, Miller M, Kloke BP, Simon P, Lower M, et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature (2017) 547(7662):222- 6.
- Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 363(8):711-23.
- Miller MJ, Foy KC, Kaumaya PT. Cancer immunotherapy: present status, future perspective, and a new paradigm of peptide immunotherapeutics. Discov Med (2013) 15(82):166-76.
- Ogi, C. & Aruga, A. Immunological monitoring of anticancer vaccines in clinical trials. Oncoimmunology 2, e26012 (2013).
- Guo C., Manjili M.H., Subjeck J.R., Sarkar D., Fisher P.B., Wang X.Y. Therapeutic cancer vaccines: past, present, and future. Adv Cancer Res. 2013;119:421-75.
Статья
